Deepinder Goyal’s Temple acquires Longevous ahead of wearable launch
Temple has acquired London-based longevity clinic Longevous for undisclosed terms, bringing founders Robert Mohr and Avi Roy in as chief medical officer and head of science. The move strengthens Temple’s clinical credentials ahead of pre-orders and a limited wearable-device launch planned for 2026.
What happened
Deepinder Goyal’s healthtech wearable startup Temple acquired London longevity clinic Longevous for undisclosed terms. Longevous founders Robert Mohr and Avi
Key facts
- More than 100,000 applications
- First 100 introductory devices
- Nearly two decades of clinical experience
- Two months of device stress-testing
Why this matters
Temple’s Longevous deal secures specialized longevity expertise and founder talent, illustrating a capability-led M&A route into the health-tech wearable market.
What to watch
- Timing, price and geography of 2026 pre-orders and limited launch.
- Whether Temple positions the product as wellness tracking or makes medical, diagnostic or disease-risk claims.
- Announcement of subscription pricing, blood-testing partnerships, clinical memberships or telehealth integration.
- Evidence of regulatory clearances, clinical trials, peer-reviewed validation or healthcare-provider partnerships.
- Founder retention and the extent to which Mohr and Roy influence product design and customer care.
- Data privacy disclosures, especially policies on biometric, clinical and wearable-derived data.
- Package the wearable with Longevous-style diagnostics, clinician consultations and paid membership tiers.
- Recruit additional medical, regulatory, data-science and hardware-validation talent to support clinical positioning.
- Pursue pilots with high-income early adopters, executive-health providers, insurers or preventive-care clinics.
- Publish validation studies, advisory-board appointments or biomarker-outcome partnerships ahead of pre-orders.
- Build consent, health-data governance and AI recommendation safeguards suitable for UK and international expansion.